Nalaganje...
Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer
Purpose: Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinases that also inhibits rearranged during transfection kinase activity. Vandetanib (300 mg/d) has previously demonstrated antitumor activity in patient...
Shranjeno v:
Main Authors: | , , , , |
---|---|
Format: | Artigo |
Jezik: | Inglês |
Izdano: |
The Endocrine Society
2010
|
Teme: | |
Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2902067/ https://ncbi.nlm.nih.gov/pubmed/20371662 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2009-2461 |
Oznake: |
Označite
Brez oznak, prvi označite!
|